Promise of Data-Driven Modeling and Decision Support for Precision Oncology and Theranostics
Binesh Sadanandan 1, Vahid Behzadan 2 · 2025
Read Promise of Data-Driven Modeling and Decision Support for Precision Oncology and Theranostics by Binesh Sadanandan 1, Vahid Behzadan 2 (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2505-09899.txt.
Introduction
Binesh Sadanandan and Vahid Behzadan review data driven decision support for precision cancer care in a 2025 paper. Cancer care works best when treatment fits the single patient. A field called theranostics pairs detailed imaging with targeted therapy to do just that. The catch is planning: doses and timing must be tuned to each body, and that is hard to do by hand.
The authors survey tools that learn from data, with a focus on reinforcement learning, where a system improves by trial and feedback. They cover training setups, how patient state is encoded, and how risk and reward are weighed. They then propose a framework that joins learning based decision support with body based drug models, sharpened by neural network methods. The goal is better dosing plans for radioactive drug therapy.
Catalog record
| CREATOR | Binesh Sadanandan 1, Vahid Behzadan 2 |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2505-09899
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Promise of Data-Driven Modeling and Decision Support for Precision Oncology and Theranostics [email protected] 1 , [email protected] 2 Binesh Sadanandan 1, Vahid Behzadan 2 Abstract Cancer remains a leading cause of death worldwide, necessitating personalized treatment approaches to improve outcomes. Theranostics, combining molecular-level imaging with targeted therapy, offers potential for precision oncology but requires optimized, patient-specific care plans. This paper investigates state-of-the-art data-driven decision support applications with a reinforcement learning focus in precision oncology. We review current applications, training environments, state-space representation, performance evaluation criteria, and measurement of risk and reward, highlighting key challenges. We propose a framework integrating data-driven modeling with reinforcement learning-based decision support to optimize radiopharmaceutical therapy dosing, addressing identified challenges and setting directions for future research. The framework leverages Neural Ordinary Differential Equations and Physics-Informed Neural Networks to enhance Physiologically Based Pharmacokinetic models while applying reinforcement learning algorithms to iteratively refine treatment policies based on patient-specific data. † † aftertitle: I Introduction Cancer, as the second leading cause of death worldwide, represents a critical threat to global public health [ 1 ] . Even in highly developed nations like the United States, its increasing incidence underscores the urgent need for continued research and preventative measures [ 1 ] . Advances in precision medicine, particularly within precision oncology, offer innovative strategies to target cancer with greater specificity and improve patient outcomes [ 2 ] . Precision medicine tailors therapeutic strategies to individual patients by accounting for genetic, cellular, and environmental factors. This personalized approach optimizes benefits while reducing costs and complications. In recent years, Radio Pharmaceutical Therapy (RPT) has emerged as a compelling treatment method for various cancer types, delivering radiation systemically or locally through radionuclides and enabling non-invasive imaging of the therapeutic agent’s biodistribution. Theranostics, combining therapy and diagnostics, integrates diagnostic tools with therapeutic agents for simultaneous or sequential visualization and treatment. This approach capitalizes on disease-specific biomarkers coupled with radioactive compounds visible through molecular imaging techniques. A key advantage is the capacity for quantitative pharmacokinetic measurement of molecular drug target uptake, facilitating imaging of therapeutic drug delivery to tumors and normal tissue. Despite promising outcomes, successful implementation of precision theranostics faces various challenges, including high costs, limited reimbursement, and hesitant attitudes among clinicians [ 3 ] . Standardized dosing regimens neglect diversity in individual physiological responses, potentially leading to overtreatment or inadequate intervention [ 4 ] . There is growing advocacy for personalized dosing strategies using early-response biomarkers to tailor treatment more precisely [ 4 ] . Computational oncology links data-centric analysis with cancer research, utilizing various mathematical and computational methodologies to explore, model, and forecast cancer dynamics. Data-driven modeling extracts knowledge directly from observed data, using advanced algorithms to identify patterns and causative links in complex datasets [ 5 , 6 ] . Reinforcement Learning (RL) has shown promise in automating intricate decision-making for personalized treatment plans. While data-driven methodologies excel at extracting patterns from static datasets, RL extends this by introducing interactive learning and adaptation through trial and error in simulated environments [ 5 , 6 , 7 , 8 ] . The contributions of this paper include: • Proposing a framework merging advanced RL with data-driven modeling to create dynamic, personalized oncology treatment plans • Introducing the application of RL algorithms to iteratively learn and refine treatment policies based on real-time patient data and simulated scenarios II Radio Pharmaceutical Therapy (RPT) A radiopharmaceutical combines a pharmaceutical component with a radioactive isotope, targeting specific biological processes. The drug’s chemical structure dictates its biological properties, ensuring it binds to specific cells associated with disease, while the radionuclide provides imaging or therapeutic capabilities. RPT targets and destroys cancerous cells through radiation-induced damage. In theranostics, X -rays and \gamma -rays serve pivotal roles in the diagnostic phase, allowing precise mapping of radiopharmaceutical distribution. The therapeutic efficacy hinges on electron emissions (Auger electrons, \beta -particles, and monoenergetic electrons) delivering localized, cytotoxic radiation to cancer cells. Patient screening for theranostic applications uses biochemically identical isotopes—one for diagnostic imaging through PET/CT, another for therapeutic purposes. For example, I-123/I-124 for imaging and I-131 for therapy in thyroid cancer; Gallium-68 for imaging and Lutetium-177 for treatment in neuroendocrine tumors. II-A Current RPT Treatments and Dosing Practices FDA-approved clinical agents include Iodine-131 for thyroid conditions, Lutetium-177 for neuroendocrine and prostate cancers, Radium-223 for bone metastases in prostate cancer, Samarium-153 for bone pain palliation, and Yttrium-90 for liver tumors and non-Hodgkin lymphoma. These agents leverage unique expression of cellular receptors or physiological differences in tissue uptake to selectively deliver radiation. The mechanism of action primarily involves binding to specific cellular receptors overexpressed in cancerous tissues. For example, Lutetium-177 labeled DOTATATE targets somatostatin receptors in neuroendocrine tumors, while PSMA-targeted therapies like Lutetium-177 PSMA target prostate-specific membrane antigen in prostate cancer cells. Radium-223, emulating calcium, selectively accumulates in bone metastases. Dosing varies widely: Iodine-131 has varying doses for thyroid conditions, Lutetium-177 uses standardized regimens for neuroendocrine tumors, and Radium-223 employs weight-based dosing for prostate cancer with bone metastases. II-B Personalized Dosimetry Dosimetry, the methodical quantification of absorbed radiation dose, leverages diagnostic imaging to tailor subsequent treatment cycles. By assessing pharmacokinetics at temporal intervals, clinicians can adjust dosage to optimize therapeutic benefits while mitigating risks to non-targeted tissues [ 9 ] . RPT utilizes the absorbed dose (D), representing energy imparted per unit mass of tissue, to dictate therapy’s biological impact. This measure is a robust indicator of expected biological response, allowing real-time pharmacodynamic evaluations [ 9 ] . Mathematically, dose is defined as D=\Delta E/\Delta m , where D is dose in Grays, \Delta E is energy absorbed, and \Delta m is mass of irradiated matter. For RPT, this is refined to D(T\leftarrow S)=\tilde{A}(S)\times S(T\leftarrow S) , where D signifies dose absorbed by target organ from radiating source organ, \tilde{A}(S) represents time-integrated activity, and S(T\leftarrow S) is the S-factor calculating dose imparted to the target for each radionuclide decay in the source organ [ 10 ] . Expanded, the formula becomes: D(T\leftarrow S)=\tilde{A}(S)\times\frac{a\times\phi(T\leftarrow S)}{M(T)} (1) where a represents total energy emitted from source organ, \varphi(T\leftarrow S) is fraction of energy absorbed in target organ, and M(T) is mass of target organ [ 10 ] . Dosimetry in RPT is complex due to variety of particle types and their distinct interactions [ 9 ] . Accurate dosimetry requires imaging resolution matching emitted particles’ spatial scale of energy deposition. Voxel-level dosimetry is generally adequate for beta emitters but may need more precise measurements for alpha emitters with short range and high ionization density. II-C Decision Support in RPT Dosimetry Several commercially available software tools support RPT dosimetry, including QDOSE, PLANET Dose, GE Dosimetry Toolkit, Rapid, and Voximetry Torch [ 11 ] . These employ three primary approaches: • Dose Factor (S value)–Based Calculation : Uses predefined S-factors representing mean dose absorbed by target organ per unit of activity in source organ, commonly applied in organ-level dosimetry [ 11 ] . • Dose-Point Kernel Convolution : Convolves dose-point kernels with activity distribution to calculate dose distribution, beneficial for voxel-level dosimetry [ 11 ] . • Monte Carlo Radiation Transport Simulation : Simulates physical processes of radiation as it travels through matter, accounting for complex geometries and stochastic nature of radiation interactions [ 11 ] . II-D PBPK Approaches Physiologically